// App-Quantinova.ai

1150 : The Echelon-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma

Researchers

Presenter

  • Steven M. Horwitz

Principal Investigators

  • Barbara Pro

  • Tim Illidge

  • Swami P. Iyer

  • Ranjana Advani

  • Nancy L. Bartlett

  • Jacob Haaber Christensen

  • Franck Morschhauser

  • Eva Domingo-Domenech

  • Giuseppe Rossi

  • Won Seog Kim

  • Tatyana A. Feldman

  • Tobias Menne

  • David Belada

  • rpd Ills

  • Kensei Tobinai

  • Kunihiro Tsukasaki

  • Su-Peng Yeh

  • Andrei R Shustov

  • Andreas Httmann

  • Kerry J. Savage

  • Sam Yuen

  • Pier Luigi Zinzani

  • Harry Miao

  • Veronica Bunn

  • Keenan Fenton

  • Michelle A. Fanale

  • Markus Puhlmann

  • Lorenz Truemper

Medical Centers

  • Department of Medicine, Leukemia Service, Memorial Sloan Kettering Cancer Center, New York, NY

  • Internal Medicine, University of Virginia, Charlottesville, VA

  • TG Therapeutics, Inc., New York, NY

  • Division of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine/Northwestern Memorial Hospital, Chicago, IL

  • Division of Cancer Sciences, Faculty of Biology, Medicine and Health,University of Manchester, NIHR Biomedical Research Centre, Manchester Academic Health Sciences Centre, Christie Hospital NHS Foundation Trust,,Manchester,United Kingdom

  • MD Anderson Cancer Center, University of Texas, Houston, TX

  • Stanford Cancer Center, Blood and Marrow Transplant Program, Stanford, CA

  • Division of Oncology, Washington University in St. Louis, St. Louis, MO

  • Odense University Hospital, Odense, Denmark

  • CHRU de Lille, Lille cedex, Nord-Pas-de-Calais, France

  • Institut Catala d'Oncologia, l'Hospitalet de Llobregat, Barcelona, Spain

  • Azienda AO Spedali Civili di Brescia, Brescia, Italy

  • Samsung Medical Center, seoul, CA, Korea, Republic of (South)

  • Hackensack University Medical Center, Oradell, NJ

  • Freeman Hospital, Newcastle upon Tyne, United Kingdom

  • Fourth Department of Internal Medicine - Hematology, Charles University Hospital and Faculty of Medicine, Hradec Kralove, Czech Republic

  • Debreceni Egyetem,Debrecen,Hungary

  • Department of Diagnostic Radiology, National Cancer Center Hospital, Tokyo, Japan

  • Saitama Medical University, International Medical Center, Department of Hematology, Saitama, Japan

  • Division of Hematology and Oncology, Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan

  • University of Washington Medical Center, Seattle, WA

  • Universitatsklinikum Essen, Essen, Nordrhein-Westfalen, Germany

  • BC Cancer Centre for Lymphoid Cancer and University of British Columbia, Vancouver, BC, Canada

  • Calvary Mater Newcastle Hospital, Waratan, Australia

  • Institute of Hematology, University of Bologna, Bologna, Italy

  • Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Deerfield, IL

  • Seattle Genetics, Bothell, WA

  • Seattle Genetics, Bothell, WA

  • Universitatsmedizin Gottingen, Gottingen, Germany

Locations

  • United States

  • Denmark

  • France

  • Spain

  • Italy

  • Republic of South Korea

  • United Kingdom

  • Czech Republic

  • Hungary

  • Japan

  • Taiwan

  • Germany

  • Canada

  • Australia

Companies

  • Seattle Genetics, In

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Peripheral T-cell lymphoma

Biomarkers

  • DNA Damage Inducible Transcript 3

Drug/Treatment

  • Adcetris

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multinational

  • Multicenteric

  • Controlled

Phase

  • III

Study Id's

  • NCT01777152

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved